Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
National Institutes Of Biomedical Innovation Health And Nutrition has 4 pending office actions in the Biotechnology and Pharmaceuticals technology area. These 4 pending office actions are handled by 4 distinct examiners. Additionally, the portfolio is active across 4 distinct art units. The fact that there are 4 distinct art units suggests that the company's technology is being reviewed by different specialized groups at the USPTO. This distribution across 4 distinct art units requires a prosecution strategy that accounts for multiple departmental standards.
The busiest examiner, CHONG, KIMBERLY, is assigned 1 busiest examiner pending office action. This 1 busiest examiner pending action is a smaller number than the total of 4 pending office actions. Because there are 4 distinct examiners, each of the 4 pending office actions is being reviewed by a different person. This means that no single examiner's preferences will apply to multiple cases. The 4 pending office actions in the Biotechnology and Pharmaceuticals area highlight a prosecution effort that is spread across the 4 distinct examiners and 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §102 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| FRUMKIN, JESSE P | 1 | 69.9% | +47.7% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17605656 | METHOD FOR DIAGNOSING ENDOMETRIOSIS, DISEASE STATE MONITORING METHOD, AND KIT | IVICH, FERNANDO NMN | 31d overdue |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 22d |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17605656 | METHOD FOR DIAGNOSING ENDOMETRIOSIS, DISEASE STATE MONITORING METHOD, AND KIT | IVICH, FERNANDO NMN | 31d overdue |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 22d |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 34d |
| 17789399 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | SZNAIDMAN, MARCOS L | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1628 | 1 |
| 1685 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | CHONG, KIMBERLY | 1636 | §103§112 | Non-Final OA | 34d | Pending | Sep 01, 2022 |
| 17789399 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | SZNAIDMAN, MARCOS L | 1628 | §102 | Final Rejection | — | Pending | Jun 27, 2022 |
| 17789402 | METHOD AND SYSTEM FOR ESTIMATING RENAL FUNCTION | FRUMKIN, JESSE P | 1685 | §101§102§103 | Final Rejection | 22d | Pending | Jun 27, 2022 |
| 17605656 | METHOD FOR DIAGNOSING ENDOMETRIOSIS, DISEASE STATE MONITORING METHOD, AND KIT | IVICH, FERNANDO NMN | 1678 | §101§102§103 | Final Rejection | 31d overdue | Pending | Oct 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Institutes Of Biomedical Innovation Health And Nutrition has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Kimberly Chong has the most, with 1 of National Institutes Of Biomedical Innovation Health And Nutrition's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
